1. Owen R.G. et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia // Seminars in Oncology. W.B. Saunders, 2003. Vol. 30, № 2. P. 110-115.
2. Kumar S.K. et al. Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). 2020.
3. Балакирева Т.В., Андреева Н.Е. Макроглобулинемия Вальденстрема // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009. Vol. 2, № 2. P. 121-136.
4. Varettoni M. et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms // Blood. American Society of Hematology, 2013. Vol. 121, № 13. P. 2522-2528.
5. Treon S.P. et al. MYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemia // N. Engl. J. Med. Massachussetts Medical Society, 2012. Vol. 367, № 9. P. 826-833.
6. Morel P. et al. International prognostic scoring system for Waldenstrom macroglobulinemia // Blood. 2009. Vol. 113, № 18. P. 4163-4170.
7. Kastritis E. et al. Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2018. Vol. 29, № Supp. 4. P. iv41-iv50.
8. Kastritis E. et al. Prognostication in young and old patients with Waldenstrom’s macroglobulinemia: Importance of the international prognostic scoring system and of serum lactate dehydrogenase // Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, № 1. P. 50-52.
9. Демина Е.А. et al. Общие принципы диагностики лимфом // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 9-27.
10. Auwerda J.J.A. et al. Prothrombotic coagulation abnormalities in patients with paraproteinproducing B-cell disorders. // Clin. Lymphoma Myeloma. 2007. Vol. 7, № 7. P. 462-466.
11. Rothschild B.M., Ruhli F., Rothschild C. Skeletal clues apparently distinguishing Waldenstrom’s macroglobulinemia from multiple myeloma and leukemia // Am. J. Hum. Biol. Wiley-Blackwell, 2002. Vol. 14, № 4. P. 532-537.
12. Rausch P.G., Herion J.C. Pulmonary manifestations of waldenstrom macroglobulinemia // Am. J. Hematol. John Wiley & Sons, Ltd, 1980. Vol. 9, № 2. P. 201-209.
13. Kyle R.A. et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia // Seminars in Oncology. W.B. Saunders, 2003. Vol. 30, № 2. P. 116-120.
14. Owen R.G. et al. Waldenstrom macroglobulinemia: Development of diagnostic criteria and identification of prognostic factors // Am. J. Clin. Pathol. 2001. Vol. 116, № 3. P. 420-428.
15. Palladini G. et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis // Circulation. Lippincott Williams and Wilkins, 2003. Vol. 107, № 19. P. 2440-2445.
16. Menke M. et al. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenstrom’s macroglobulinemia // Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, № 1. P. 100-103.
17. Brandefors L. et al. Prognostic factors and primary treatment for Waldenstrom macroglobulinemia - a Swedish Lymphoma Registry study // Br. J. Haematol. Blackwell Publishing Ltd, 2018. Vol. 183, № 4. P. 564-577.
18. Dimopoulos M.A. et al. Predictive factors for response to rituximab in Waldenstrom’s macroglobulinemia. // Clin. Lymphoma. 2005. Vol. 5, № 4. P. 270-272.
19. Treon S.P. et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 // J. Clin. Oncol. 2009. Vol. 27, № 23. P. 3830-3835.
20. Ghobrial I.M. et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia // Am. J. Hematol. Wiley-Liss Inc., 2010. Vol. 85, № 9. P. 670-674.
21. Dimopoulos M.A. et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide // J. Clin. Oncol. 2007. Vol. 25, № 22. P. 3344-3349.
22. Buske C. et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) // Leukemia. Nature Publishing Group, 2009. Vol. 23, № 1. P. 153-161.
23. Treon S.P. et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen // Br. J. Haematol. 2011. Vol. 154, № 3. P. 357-362.
24. Chen C.I. et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom’s macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group // J. Clin. Oncol. 2007. Vol. 25, № 12. P. 1570-1575.
25. Paludo J. et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia // Ann. Hematol. Springer Verlag, 2018. Vol. 97, № 8. P. 1417-1425.
26. Treon S.P. et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia // Blood. 2009. Vol. 113, № 16. P. 3673-3678.
27. Laszlo D. et al. Rituximab and subcutaneous 2-chloro-2’-deoxyadenosine as therapy in untreated and relapsed Waldenstrom’s macroglobulinemia // Clinical Lymphoma, Myeloma and Leukemia. 2011. Vol. 11, № 1. P. 130-132.
28. Tedeschi A. et al. Fludarabine plus cyclophosphamide and rituximab in waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease // Cancer. 2012. Vol. 118, № 2. P. 434-443.